Table 3A.

Effect of the STRIDE Intervention on Patient-Reported Outcomes at 12 Weeks: Results of Analysis of Covariance Models (n=92)

Patient-Reported Outcome	Adjusted Mean at 12 weeks [95% CI]
	Medication Monitoring	STRIDE Intervention	Beta [95% CI]	Cohen’s d	p-value
Self-Reported Adherence (MARS-5)	23.86 [23.49, 24.23]	23.99 [23.61, 24.36]	0.13 [−0.40, 0.66]	0.07	.630
Symptom Distress (BCPT)	20.67 [18.82, 22.53]	19.89 [17.98, 21.79]	−0.79 [−3.49, 1.91]	0.08	.562
Hot Flashes Distress (BCPT)	3.38 [2.89, 3.87]	2.67 [2.17, 3.17]	−0.72 [−1.43, −0.01]	0.31	.048 *
Satisfaction with Therapy (CTSQ)	63.94 [61.30, 66.58]	66.53 [63.82, 69.23]	2.58 [−1.27, 6.44]	0.21	.186
Quality of Life (FACT-B)	107.68 [104.66, 110.71]	111.96 [108.88, 115.04]	4.28 [−0.11, 8.67]	0.23	.056 +
Coping Skills (MOCS-A)	28.49 [26.42, 30.57]	32.90 [30.78, 35.02]	4.41 [1.39, 7.43]	0.48	.005 **
Symptom Self-Management (SESM-AET)	5.34 [4.84, 5.85]	6.03 [5.51, 6.54]	0.68 [−0.05, 1.41]	0.35	.067 +
Depressive Symptoms (HADS-D)	4.26 [3.56, 4.96]	3.87 [3.17, 4.58]	−0.38 [−1.39, 0.63]	0.12	.451
Anxiety Symptoms (HADS-A)	6.59 [5.66, 7.51]	6.54 [5.61, 7.47]	−0.05 [−1.38, 1.29]	0.01	.946

Note: CI = Confidence Interval; Beta = Difference in adjusted mean score (STRIDE minus Medication Monitoring); All analyses are adjusted for Ovarian Suppression Receipt (Yes vs. No), Baseline Distress Level (Elevated vs. Not Elevated [Elevated= HADS anxiety or depression subscale ≥ 8]), and Baseline Value of the Outcome of Interest.

⁺p<.1,

^*p<.05,

^**p<.01,

^***p<.001

Abbreviations: MARS = Medication Adherence Rating Scale; BCPT = Breast Cancer Prevention Trial Checklist; CTSQ = Cancer Therapy Satisfaction Questionnaire; FACT = Functional Assessment of Cancer Therapy (Breast); MOCS-A = Measure of Current Status Part A; SESM-AET = Self-Efficacy for Managing Symptoms of Adjuvant Endocrine Therapy; HADS = Hospital Anxiety and Depression Scale [A = Anxiety; D = Depression).